Please assess the completion status of the following clinical trial:

Trial Title: S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive breast cancer~  * Stage I-IIIA~ * Operable disease~* Bilateral synchronous invasive breast cancer allowed provided primary tumors were diagnosed no more than 1 month apart and both tumors are hormone receptor negative~* Must be planning to receive 3-8 months of a preoperative or postoperative chemotherapy regimen containing alkylating agents (anthracyclines or non-anthracyclines), meeting 1 of the following criteria:~  * 3-month/4-course anthracycline-based regimen~ * 6- to 8-month/course anthracycline-based regimen~ * 6- to 8-month/course non-anthracycline-based regimen~* Hormone receptor status:~  * Estrogen receptor negative~ * Progesterone receptor negative~PATIENT CHARACTERISTICS:~Age~* 18 to 49~Sex~* Female~Menopausal status~* Premenopausal~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Fertile patients must use effective barrier contraception~* No other prior malignancy except adequately treated basal cell or squamous cell skin cancer or any in situ cancer from which the patient has been disease-free for at least 5 years after treatment with curative intent~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~* No prior cytotoxic chemotherapy~Endocrine therapy~* No other concurrent hormonal therapy~Radiotherapy~* Concurrent radiotherapy to the breast, chest wall, or lymph nodes allowed~Surgery~* See Disease Characteristics~Other~* Concurrent participation in other therapeutic clinical trials, including SWOG-S0221, allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Standard Chemotherapy (Type: ACTIVE_COMPARATOR): Patients receive cyclophosphamide-containing chemotherapy alone.
- Chemotherapy Plus Goserelin (Type: EXPERIMENTAL): Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).